Petrova and colleagues designed a genetically modified MSC for expressing collagen type VII alpha 1 chain (COL7A1) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) [92]. Here, COL7A1 is linked to recessive dystrophic epidermolysis bullosa inversa.